Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dopamine receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Dopamine receptor. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-001284-12 Sponsor Protocol Number: PA-01 Start Date*: 2014-11-19
    Sponsor Name:University Medical Center Groningen
    Full Title: The Role of the Dopamine D2 Receptor System in Pornographic Addiction – A [11C]-Raclopride PET Study
    Medical condition: pornographic addiction
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004062-41 Sponsor Protocol Number: D2PET-2007 Start Date*: 2007-08-13
    Sponsor Name:Jarmo Hietala
    Full Title: Effect differences of conventional and newer atypical antipsychotics – Perphenazine and brain dopamine D2 receptor blockade
    Medical condition: Tutkittavat ovat terveitä.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003131-38 Sponsor Protocol Number: DOPA2016 Start Date*: 2017-06-23
    Sponsor Name:TARGID, KU Leuven
    Full Title: The effect of chlorpromazine (Largactil), a dopamine type 2-(D2-) receptor antagonist, on esophageal sensitivity in healthy volunteers: a randomized, double-blind, placebo-controlled study
    Medical condition: Increased esophageal sensitivity in refractory gastro-esophageal reflux disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010282-23 Sponsor Protocol Number: Bruxism-01 Start Date*: 2010-10-26
    Sponsor Name:Tandvården SU/Mölndal
    Full Title: A randomized, open-label, cross-over study to explore a potential involvement of a dopamine related dysfunction as a mechanism behind bruxism
    Medical condition: Patients with severe oral bruxism according to Polysomnographic cut-off criteria for bruxism: more than 4 bruxism episodes per hour, more than 6 bruxism bursts per episode and/or 25 bruxism bursts ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028037 Movement disorders (incl parkinsonism) HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003343-11 Sponsor Protocol Number: GLP1ALCOHOL Start Date*: 2017-04-12
    Sponsor Name:Psychiatric Centre Copenhagen
    Full Title: Does Glucagon-like Peptide 1 (GLP-1) receptor stimulation reduce alcohol intake in patients with alcohol dependence?
    Medical condition: Alcohol dependence
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10001125 Addiction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005538-59 Sponsor Protocol Number: 22-09-2008 Start Date*: 2009-02-18
    Sponsor Name:ZonMw
    Full Title: Impulsivity, a risk factor in relapse to substance use disorder: investigating neural substrates before and after pharmacological challenges
    Medical condition: Alcohol dependence Cocaine dependence
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001108-35 Sponsor Protocol Number: NRA 6290010 Start Date*: 2006-07-03
    Sponsor Name:Clinic of University of Wuerzburg
    Full Title: CHANGES OF LEFT VENTRICULAR MASS AND CARDIAC FUNCTION IN PATIENTS WITH ACTIVE ACROMEGALY DURING TREATMENT WITH THE GROWTH HORMONE RECEPTOR ANTAGONIST PEGVISOMANT: AN OPEN-LABELLED, PROSPECTIVE STUDY
    Medical condition: Somavert (Pegvisomant) is approved for the treatment of acromegalic patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapy as Somatostatin Ana...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061835 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001028-23 Sponsor Protocol Number: T1010-01 Start Date*: 2017-08-02
    Sponsor Name:Tools4Patient
    Full Title: Validation Study to Investigate the Effect of T4P1010 treatment in Patients with Osteoarthritic Pain of Knee or Hip.
    Medical condition: Osteoarthritic pain of knee or hip.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10023476 Knee osteoarthritis LLT
    20.0 100000004859 10020108 Hips osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-004989-14 Sponsor Protocol Number: Start Date*: 2007-01-12
    Sponsor Name:Christie Hospital NHS Trust
    Full Title: The Effect of Raloxifene on Serum IGF-I in Patients with Acromegaly on long-term Octeotide Treatment
    Medical condition: acromegaly
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005852-42 Sponsor Protocol Number: CSMS995BIC03 Start Date*: 2007-04-20
    Sponsor Name:NOVARTIS FARMA
    Full Title: An open-label, two-step, multicenter European study to evaluate the efficacy and safety of Sandostatin LAR at High Dose or in combination either with GH-receptor antagonist or dopamine-agonist i...
    Medical condition: acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005218-13 Sponsor Protocol Number: 2167SR Start Date*: 2012-04-23
    Sponsor Name:Kings College London [...]
    1. Kings College London
    2. South London and Maudsley NHS Foundation Trust
    Full Title: Rationalisation of antipsychotic drug use in older people, using [18F]-Fallypride PET
    Medical condition: Alzheimer's Disease and schizophrenia like illness
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004852 10001896 Alzheimer's disease LLT
    17.0 100000004873 10032928 Other specified types of schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006949-13 Sponsor Protocol Number: BRD/06/162 Start Date*: 2007-10-16
    Sponsor Name:University College London
    Full Title: A multi-centre exploratory study to evaluate the efficacy of the dopamine receptor agonist rotigotine in the treatment of hemispatial neglect and motor deficits following stroke.
    Medical condition: Hemispatial neglect and motor deficits following right-hemisphere stroke.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042244 Stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000206-36 Sponsor Protocol Number: DOPA1 Start Date*: 2014-10-27
    Sponsor Name:
    Full Title: DRD4 genotype as a moderator of L-Dopa intervention effects on parent-related neurocognitive processes, behaviors, and attitudes: A micro-trial of differential susceptibility to pharmacological int...
    Medical condition: There are no medical conditions or diseases under investigation.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001890-15 Sponsor Protocol Number: SD-809-C-18 Start Date*: 2014-11-12
    Sponsor Name:Auspex Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA
    Medical condition: Tardive Dyskinesia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-007669-20 Sponsor Protocol Number: 37822681SCH2003 Start Date*: 2008-08-18
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Double-Blind, Multiple Dose Titration Study to Investigate the Safety, Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses of JNJ-37822681 in Male and Female Patients With Stabl...
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Prematurely Ended) BE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-003135-19 Sponsor Protocol Number: SD-809-C-23 Start Date*: 2015-02-06
    Sponsor Name:Auspex Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA
    Medical condition: Tardive Dyskinesia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed) CZ (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001292-51 Sponsor Protocol Number: CH-ACM-01-FU Start Date*: 2015-06-30
    Sponsor Name:Chiasma, Inc.
    Full Title: Follow-Up Study in Patients with Acromegaly Previously Participating in Chiasma Study CH-ACM-01
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SI (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004259-22 Sponsor Protocol Number: ISIS766720-CS2 Start Date*: 2018-06-05
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor) Administered...
    Medical condition: Acromegaly is a chronic disorder caused by GH hypersecretion, most commonly as a result of a GH-secreting pituitary adenoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) LT (Completed) CZ (Prematurely Ended) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-011115-20 Sponsor Protocol Number: NordLOTS protocol step 3 1.1 Start Date*: 2009-08-14
    Sponsor Name:The Centre for Child and Adolescent Mental Health, Eastern and Southern Norway (R.BUP)
    Full Title: Nordic Longterm OCD treatment Study: A Nordic Multicenter treatment study evaluating a stepped care model based on the "Expert Clinical Guidelines". The study is performed with no sponsor from phar...
    Medical condition: Obsessive Compulsive Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049596 Obsession LLT
    9.1 10010219 Compulsions LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing) NO (Ongoing) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002950-22 Sponsor Protocol Number: CVL-751-PD-002 Start Date*: 2020-05-19
    Sponsor Name:Cerevel Therapeutics, LLC
    Full Title: A Phase 3, Double-Blind, Randomized, Placebo Controlled, Parallel Group, Flexible-Dose, 27 Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson’s Disease (T...
    Medical condition: Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 14:31:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA